

No: A (01)/PSW/DO/DRAP-1842/20223

Islamabad, 13th November 2023

Mr. Ishtiaq Shafique,
Assistant Director DRAP, Focal Person PSW,
DRAP Regional Office, 6-BirdWood Road,
Lahore.

Subject: SWITCH OVER TO PSW FOR ISSUANCE OF DRUG IMPORT LICENCE (ALL TYPES) AND RELEASE ORDER OF UNREGISTERED DRUGS FOR DONATION PURPOSES FOR HOSPITALS AND NGOS


I am directed to refer to PSW's letter No. PSW/FO/DRAP-91/2023 dated 10th April 2023 and to inform that the integration of Drug Regulatory Authority of Pakistan (DRAP) with PSW system is being rolled out in phases. In first phase, DRAP's Entity & Product Registration module has been successfully incorporated into the PSW system for the holders of Drug Manufacturing License, Drug Sale License, and Drug Import License since 10th April 2023.

2. Now, it is brought to your attention that w.e.f. 30th November 2023, the submission and issuance of Drug import licenses (all types) and the Release Order for donated unregistered drugs imported by Hospitals/NGOs will be shifted to the PSW system. In order to ensure smooth transition to PSW platform, DRAP is requested to make advance preparations.

3. PSW Change Management team in consultation with the DRAP has been successfully conducting training and awareness sessions for DRAP officers and the Pharmaceutical Industry since the roll-out of Phase 1. Therefore, in continuation of these efforts,

it is requested to nominate the concerned field officers for the upcoming training sessions which are scheduled to be held from 16th November 2023. These training sessions will be conducted both in person and virtually.

4. Furthermore, it is also requested to inform all existing and prospective DIL holders and NGOs/Hospitals engaged in the import of unregistered products may be informed to file their respective requests through PSW system w.e.f. 30th November 2023.


(Umair Mahmood Siddiqui)
Domain Officer

Distribution:

1. The Secretary Ministry of National Health Services Regulations and Coordination, Islamabad
2. The Member Customs (Operations), Federal Board of Revenue, Islamabad
3. The Chief Executive Officer, Drug Regulatory Authority of Pakistan, Islamabad
4. The Chief Executive Officer, Pakistan Single Window, Islamabad
5. The Director General, National Institutes of Health Islamabad
6. All concerned Pharmaceutical Trade Bodies and Associations